NASDAQ · Biotechnology

Scribe Therapeutics Inc. (SCTX) Stock

$26.00 +2.32% NASDAQ: SCTX Healthcare

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Valuation

MetricValue
Price$26.00
Market Cap$420.73M
P/E Ratio—
P/B Ratio—
P/S Ratio9.13
EPS (TTM)—
52-Week High$26.50
52-Week Low$17.31
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin-54.65%
Operating Margin-556.52%
Net Margin-98.48%
Debt/Equity—
Current Ratio0.66

Latest News

Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO GuruFocus.com · Jul 24, 2026 Top Midday Gainers MT Newswires · Jul 24, 2026 Sector Update: Healthcare Stocks Rise in Afternoon Trading MT Newswires · Jul 24, 2026 Scribe Therapeutics Prices Upsized IPO at $15 per Share MT Newswires · Jul 24, 2026 Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire · Jul 24, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held11.46%
Institutions Held15.64%
Institutions Float Held17.67%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Scribe Therapeutics Inc.

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Scribe Therapeutics Inc. is headquartered in US.

Scribe Therapeutics Inc. (SCTX) stock trades at $26.00 with a market capitalization of $420.73M. The stock is valued at price-to-sales of 9.13. Over the past 52 weeks the stock has ranged between $17.31 and $26.50, and currently trades 1.9% below its 52-week high.

On profitability, Scribe Therapeutics Inc. generates an operating margin of -556.52%, a net profit margin of -98.48%.

Official website: www.scribetx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides